CD86 and neoplasm: ICBs can decrease the negative immunomodulation exerted by tumor cells/Tregs through PD-1/PD-L1 and CTLA-4/B7-1, B7-2 pathways and thus restore antitumor effects of T cells [67, 175, 176].